aztreonam

(redirected from Cayston)
Also found in: Dictionary, Thesaurus, Wikipedia.

aztreonam

 [az´tre-o-nam″]
a narrow-range antibiotic effective against aerobic gram-negative bacteria; used for the treatment of infections caused by susceptible organisms. Administered intravenously or intramuscularly.

aztreonam

/az·tre·o·nam/ (az´tre-o-nam″) a narrow-range monobactamantibiotic effective against aerobic gram-negative bacteria.

aztreonam

(ăz-trē′ə-năm′)
n.
A synthetic antibiotic, C13H17N5O8S2, that acts against a wide spectrum of gram-negative bacteria.

aztreonam

A BETA-LACTAM antibiotic effective against aerobic GRAM NEGATIVE organisms. A brand name is Azactam.

aztreonam

a monobactam, β-lactam antibiotic, very resistant to β-lactamase, but with a narrow range of activity. It is used parenterally against infections with gram-negative organisms, particularly Pseudomonas aeruginosa.
References in periodicals archive ?
Adverse reactions occurring in more than 5 percent of patients treated with Cayston compared to placebo in Phase III studies were cough (54 percent versus 51 percent), nasal congestion (16 percent versus 12 percent), wheezing (16 percent versus 10 percent), pharyngolaryngeal pain (12 percent versus 11 percent), pyrexia (13 percent versus 6 percent), chest discomfort (8 percent versus 6 percent), abdominal pain (7 percent versus 5 percent) and vomiting (6 percent versus 4 percent).
The approval of Cayston demonstrates that our drug development model is working and making a real difference in the lives of people with cystic fibrosis," said Robert J.
Cayston received conditional marketing authorizations in the European Union and Canada in September 2009 and was approved in Australia in January 2010.
June 21 /PRNewswire/ -- In a head-to-head, Phase III clinical trial of Cayston delivered by the Altera Nebulizer System versus tobramycin inhalation solution in cystic fibrosis patients with Pseudomonas aeruginosa, the co-primary endpoint of non-inferiority for mean percent change in forced expiratory volume in one second (FEV(1)) percent predicted after 28 days of treatment was achieved.
Cayston contains aztreonam formulated with lysine, a proprietary formulation of aztreonam developed specifically for inhalation.
The increase in sales of other products was due primarily to sales volume growth of AmBisome in Europe and Latin America and Cayston in the United States.
The unique liposomal formulation improves the pharmacokinetic profile to once daily, versus twice daily and three times a day for TOBI (tobramycin) and Cayston (aztreonam), respectively.
In Phase II clinical trials FTI was shown to be safe and to effectively maintain improvement in lung function achieved with Cayston in CF patients with Pseudomonas aeruginosa infection.
Truvada, Viread, Hepsera, Complera, Eviplera, Emtriva, AmBisome, Letairis, Cayston, Ranexa and Volibris are registered trademarks of Gilead Sciences, Inc.
Contract award: supply of medication cayston * nebul 75 mg 84fl +88 f + ne.
Voluntary ex ante transparency notice: supply of drug cayston 75mg 84fl +88 f + e - cig 5500927490.